Product Description
ISM5411, also known as ISM012-042, is an oral, gut-restricted small molecule inhibitor of PHD1/2 for the treatment of Inflammatory Bowel Disease ("IBD"). (Sourced from: https://www1.hkexnews.hk/app/sehk/2023/105489/documents/sehk23062701667.pdf)
Mechanisms of Action: PHD1 Inhibitor, PHD2 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: InSilico Medicine
Company Location: Asia Pacific
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, China
Active Clinical Trial Count: 3
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Colitis, Ulcerative
Phase 1: Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT07265570 |
ISM5411-201 | P2 |
Recruiting |
Colitis, Ulcerative |
2027-08-15 |
12% |
2025-12-06 |
Primary Endpoints |
CTR20241789 |
CTR20241789 | P1 |
Completed |
Healthy Volunteers |
2024-11-01 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
NCT06012578 |
ISM5411-101 | P1 |
Completed |
Healthy Volunteers |
2024-09-04 |
69% |
2024-11-08 |